| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Natriuretic Peptide, Brain | 171 | 2023 | 1573 | 23.990 |
Why?
|
| Heart Failure | 264 | 2024 | 10900 | 17.760 |
Why?
|
| Peptide Fragments | 141 | 2023 | 5097 | 13.990 |
Why?
|
| Troponin T | 52 | 2023 | 754 | 7.950 |
Why?
|
| Natriuretic Peptides | 28 | 2023 | 150 | 6.950 |
Why?
|
| Troponin I | 29 | 2022 | 619 | 6.770 |
Why?
|
| Troponin | 26 | 2024 | 524 | 5.800 |
Why?
|
| Stroke Volume | 74 | 2024 | 5007 | 5.730 |
Why?
|
| Dyspnea | 40 | 2020 | 1303 | 5.160 |
Why?
|
| Receptors, Cell Surface | 32 | 2015 | 2866 | 4.950 |
Why?
|
| Myocardial Infarction | 63 | 2024 | 11727 | 4.290 |
Why?
|
| Acute Coronary Syndrome | 33 | 2024 | 2337 | 3.820 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 8 | 2020 | 216 | 3.680 |
Why?
|
| Ventricular Dysfunction, Left | 25 | 2023 | 2073 | 3.610 |
Why?
|
| Ventricular Remodeling | 17 | 2022 | 1224 | 3.560 |
Why?
|
| Galectin 3 | 12 | 2016 | 227 | 3.340 |
Why?
|
| Chest Pain | 16 | 2022 | 1114 | 3.260 |
Why?
|
| Prognosis | 154 | 2023 | 29063 | 3.120 |
Why?
|
| Cardiovascular Diseases | 47 | 2024 | 15165 | 3.060 |
Why?
|
| Protein Precursors | 27 | 2018 | 1154 | 2.810 |
Why?
|
| Heart Failure, Systolic | 9 | 2021 | 126 | 2.780 |
Why?
|
| Coronary Angiography | 24 | 2023 | 4577 | 2.600 |
Why?
|
| Ventricular Function, Left | 22 | 2024 | 3670 | 2.210 |
Why?
|
| Tetrazoles | 7 | 2023 | 835 | 2.200 |
Why?
|
| Coronary Stenosis | 7 | 2023 | 834 | 2.120 |
Why?
|
| Neprilysin | 7 | 2020 | 439 | 2.070 |
Why?
|
| Atrial Natriuretic Factor | 13 | 2022 | 393 | 2.040 |
Why?
|
| Humans | 531 | 2024 | 744343 | 2.030 |
Why?
|
| Coronary Artery Disease | 23 | 2023 | 6487 | 2.010 |
Why?
|
| Predictive Value of Tests | 83 | 2023 | 15076 | 2.000 |
Why?
|
| Diabetes Mellitus, Type 2 | 22 | 2024 | 11725 | 1.990 |
Why?
|
| Acute Disease | 72 | 2020 | 7149 | 1.970 |
Why?
|
| Angiotensin Receptor Antagonists | 10 | 2023 | 924 | 1.920 |
Why?
|
| Biphenyl Compounds | 11 | 2023 | 913 | 1.840 |
Why?
|
| Diabetic Cardiomyopathies | 3 | 2024 | 96 | 1.840 |
Why?
|
| Proteomics | 8 | 2023 | 3638 | 1.790 |
Why?
|
| Risk Assessment | 69 | 2020 | 23338 | 1.730 |
Why?
|
| Aged | 216 | 2024 | 163280 | 1.560 |
Why?
|
| Heart Diseases | 20 | 2021 | 2788 | 1.530 |
Why?
|
| C-Reactive Protein | 18 | 2022 | 3778 | 1.530 |
Why?
|
| Male | 286 | 2024 | 350118 | 1.390 |
Why?
|
| Middle Aged | 229 | 2024 | 213383 | 1.390 |
Why?
|
| Cardiology | 16 | 2024 | 1668 | 1.390 |
Why?
|
| Myocardial Ischemia | 13 | 2022 | 2148 | 1.380 |
Why?
|
| Female | 293 | 2024 | 380194 | 1.320 |
Why?
|
| Growth Differentiation Factor 15 | 7 | 2016 | 176 | 1.300 |
Why?
|
| Cardiovascular Agents | 10 | 2020 | 850 | 1.290 |
Why?
|
| Renal Insufficiency | 10 | 2018 | 804 | 1.280 |
Why?
|
| Diuretics | 8 | 2020 | 592 | 1.270 |
Why?
|
| Endothelin-1 | 4 | 2018 | 314 | 1.260 |
Why?
|
| Coronary Disease | 18 | 2018 | 6077 | 1.250 |
Why?
|
| Diabetic Nephropathies | 3 | 2023 | 984 | 1.240 |
Why?
|
| Echocardiography | 26 | 2020 | 5102 | 1.240 |
Why?
|
| Clinical Trials as Topic | 22 | 2023 | 7913 | 1.220 |
Why?
|
| Adrenergic beta-Antagonists | 10 | 2023 | 1240 | 1.200 |
Why?
|
| Patient Readmission | 16 | 2023 | 3114 | 1.180 |
Why?
|
| Consensus | 12 | 2024 | 2959 | 1.180 |
Why?
|
| Disease Management | 11 | 2021 | 2459 | 1.170 |
Why?
|
| Angiography | 5 | 2022 | 1639 | 1.100 |
Why?
|
| Anterior Wall Myocardial Infarction | 2 | 2023 | 45 | 1.090 |
Why?
|
| Prospective Studies | 81 | 2023 | 53288 | 1.080 |
Why?
|
| Lipocalins | 5 | 2015 | 170 | 1.070 |
Why?
|
| Severity of Illness Index | 44 | 2022 | 15540 | 1.040 |
Why?
|
| Risk Factors | 96 | 2023 | 72290 | 1.040 |
Why?
|
| Emergency Service, Hospital | 32 | 2021 | 7659 | 1.040 |
Why?
|
| Heart Failure, Diastolic | 3 | 2016 | 69 | 1.020 |
Why?
|
| Outpatients | 6 | 2018 | 1486 | 1.020 |
Why?
|
| Acute Kidney Injury | 6 | 2022 | 1972 | 1.000 |
Why?
|
| Tyrosine | 8 | 2004 | 1461 | 1.000 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2023 | 2208 | 0.990 |
Why?
|
| Intramolecular Oxidoreductases | 3 | 2013 | 109 | 0.970 |
Why?
|
| Cardiovascular System | 4 | 2024 | 832 | 0.960 |
Why?
|
| Lipoprotein(a) | 4 | 2023 | 435 | 0.950 |
Why?
|
| Chronic Disease | 30 | 2022 | 9146 | 0.940 |
Why?
|
| Artificial Intelligence | 3 | 2023 | 2214 | 0.940 |
Why?
|
| Cystatin C | 5 | 2022 | 250 | 0.930 |
Why?
|
| ROC Curve | 21 | 2020 | 3527 | 0.910 |
Why?
|
| Follow-Up Studies | 53 | 2022 | 39050 | 0.850 |
Why?
|
| Patient Care Management | 3 | 2020 | 306 | 0.840 |
Why?
|
| Aortic Aneurysm | 11 | 2009 | 643 | 0.820 |
Why?
|
| Plaque, Atherosclerotic | 5 | 2023 | 1519 | 0.820 |
Why?
|
| Treatment Outcome | 71 | 2023 | 63114 | 0.820 |
Why?
|
| Glomerular Filtration Rate | 13 | 2023 | 2170 | 0.810 |
Why?
|
| Practice Guidelines as Topic | 15 | 2020 | 7279 | 0.800 |
Why?
|
| Angina, Unstable | 8 | 2019 | 926 | 0.800 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 7 | 2022 | 1518 | 0.800 |
Why?
|
| Creatinine | 13 | 2023 | 1919 | 0.800 |
Why?
|
| Glucosides | 3 | 2021 | 451 | 0.790 |
Why?
|
| Cardiac Resynchronization Therapy | 6 | 2020 | 531 | 0.760 |
Why?
|
| Expert Testimony | 3 | 2020 | 356 | 0.760 |
Why?
|
| Coronary Artery Bypass | 9 | 2021 | 2289 | 0.760 |
Why?
|
| Panic Disorder | 3 | 2014 | 616 | 0.750 |
Why?
|
| Electrocardiography | 19 | 2019 | 6442 | 0.750 |
Why?
|
| Systole | 5 | 2017 | 958 | 0.750 |
Why?
|
| Drug Combinations | 9 | 2023 | 1959 | 0.750 |
Why?
|
| Hospitalization | 29 | 2022 | 10262 | 0.740 |
Why?
|
| Research Report | 3 | 2020 | 355 | 0.730 |
Why?
|
| Aged, 80 and over | 70 | 2024 | 57776 | 0.720 |
Why?
|
| Pyridazines | 1 | 2022 | 202 | 0.720 |
Why?
|
| Proportional Hazards Models | 23 | 2022 | 12354 | 0.710 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2020 | 451 | 0.710 |
Why?
|
| Adrenomedullin | 5 | 2017 | 87 | 0.710 |
Why?
|
| Hypertension | 11 | 2023 | 8480 | 0.700 |
Why?
|
| Time Factors | 45 | 2020 | 40075 | 0.700 |
Why?
|
| Calcitonin | 3 | 2015 | 336 | 0.700 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2023 | 290 | 0.700 |
Why?
|
| Hyperlipoproteinemias | 1 | 2019 | 20 | 0.690 |
Why?
|
| Baroreflex | 1 | 2020 | 146 | 0.690 |
Why?
|
| Inpatients | 11 | 2014 | 2518 | 0.680 |
Why?
|
| Cardiac Output, Low | 3 | 2015 | 195 | 0.670 |
Why?
|
| Benzhydryl Compounds | 3 | 2021 | 845 | 0.670 |
Why?
|
| Depression | 15 | 2017 | 7766 | 0.670 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2022 | 365 | 0.670 |
Why?
|
| Heparin | 9 | 2010 | 1637 | 0.660 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 7 | 2004 | 641 | 0.640 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 3 | 2020 | 135 | 0.630 |
Why?
|
| Myocardium | 11 | 2017 | 4776 | 0.630 |
Why?
|
| Dyslipidemias | 2 | 2022 | 849 | 0.620 |
Why?
|
| Sensitivity and Specificity | 29 | 2021 | 14722 | 0.610 |
Why?
|
| Manuscripts as Topic | 1 | 2017 | 15 | 0.600 |
Why?
|
| Registries | 21 | 2019 | 8089 | 0.600 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2022 | 793 | 0.590 |
Why?
|
| Peripheral Arterial Disease | 2 | 2018 | 1188 | 0.590 |
Why?
|
| Cardiotonic Agents | 1 | 2020 | 535 | 0.590 |
Why?
|
| Cause of Death | 11 | 2020 | 3584 | 0.590 |
Why?
|
| Spironolactone | 3 | 2021 | 382 | 0.580 |
Why?
|
| Apolipoproteins | 1 | 2019 | 317 | 0.580 |
Why?
|
| Peroxidase | 2 | 2017 | 611 | 0.580 |
Why?
|
| Disease Progression | 19 | 2020 | 13284 | 0.580 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2022 | 689 | 0.570 |
Why?
|
| Kidney Function Tests | 7 | 2018 | 684 | 0.570 |
Why?
|
| Diagnosis, Differential | 28 | 2019 | 12959 | 0.570 |
Why?
|
| Furosemide | 1 | 2017 | 167 | 0.570 |
Why?
|
| Inflammation | 10 | 2022 | 10638 | 0.570 |
Why?
|
| Intensive Care Units | 11 | 2017 | 3679 | 0.570 |
Why?
|
| Diabetes Complications | 2 | 2022 | 1359 | 0.560 |
Why?
|
| Kidney | 7 | 2022 | 7186 | 0.560 |
Why?
|
| Neurotensin | 1 | 2016 | 61 | 0.550 |
Why?
|
| Protease Inhibitors | 1 | 2020 | 791 | 0.550 |
Why?
|
| Catheterization | 3 | 2018 | 1470 | 0.550 |
Why?
|
| Coronary Vessels | 5 | 2019 | 3107 | 0.540 |
Why?
|
| Renin-Angiotensin System | 2 | 2018 | 759 | 0.530 |
Why?
|
| Ventricular Function | 1 | 2017 | 416 | 0.530 |
Why?
|
| Glycopeptides | 2 | 2014 | 224 | 0.530 |
Why?
|
| Blood Proteins | 2 | 2018 | 1124 | 0.520 |
Why?
|
| Catheters | 1 | 2018 | 425 | 0.520 |
Why?
|
| Imidazoles | 1 | 2022 | 1206 | 0.520 |
Why?
|
| Hypoglycemic Agents | 7 | 2023 | 2872 | 0.520 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2015 | 87 | 0.520 |
Why?
|
| Shock | 4 | 2008 | 318 | 0.510 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2015 | 173 | 0.510 |
Why?
|
| Survival Analysis | 22 | 2019 | 10252 | 0.510 |
Why?
|
| Receptors, Interleukin-1 | 5 | 2018 | 262 | 0.500 |
Why?
|
| Incidence | 21 | 2023 | 20947 | 0.500 |
Why?
|
| Cachexia | 1 | 2016 | 204 | 0.500 |
Why?
|
| Multivariate Analysis | 24 | 2018 | 12245 | 0.500 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 1 | 2017 | 161 | 0.500 |
Why?
|
| Kidney Diseases | 7 | 2022 | 2149 | 0.500 |
Why?
|
| Catheterization, Peripheral | 1 | 2018 | 345 | 0.500 |
Why?
|
| Creatine Kinase | 9 | 2014 | 694 | 0.480 |
Why?
|
| Anxiety Disorders | 6 | 2013 | 2690 | 0.480 |
Why?
|
| Heart Ventricles | 7 | 2019 | 3821 | 0.480 |
Why?
|
| Peer Review, Research | 1 | 2017 | 329 | 0.470 |
Why?
|
| Stroke | 10 | 2023 | 9981 | 0.470 |
Why?
|
| United States | 44 | 2024 | 69872 | 0.460 |
Why?
|
| Cohort Studies | 40 | 2022 | 40561 | 0.450 |
Why?
|
| Diabetes Mellitus | 6 | 2023 | 5751 | 0.450 |
Why?
|
| Fibrinolytic Agents | 7 | 2018 | 2158 | 0.450 |
Why?
|
| Oxygen Consumption | 2 | 2017 | 1869 | 0.450 |
Why?
|
| Prevalence | 16 | 2022 | 15226 | 0.440 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 1519 | 0.430 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1071 | 0.420 |
Why?
|
| Shock, Cardiogenic | 2 | 2017 | 688 | 0.410 |
Why?
|
| Serum Albumin | 3 | 2010 | 676 | 0.410 |
Why?
|
| Survival Rate | 19 | 2019 | 12788 | 0.410 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 162 | 0.410 |
Why?
|
| Research | 1 | 2020 | 1999 | 0.400 |
Why?
|
| Cardiac Imaging Techniques | 3 | 2018 | 269 | 0.400 |
Why?
|
| Lung Diseases | 2 | 2015 | 1886 | 0.400 |
Why?
|
| Heart | 3 | 2021 | 4467 | 0.400 |
Why?
|
| Quality of Life | 13 | 2024 | 12804 | 0.400 |
Why?
|
| International Classification of Diseases | 4 | 2021 | 867 | 0.400 |
Why?
|
| Contrast Media | 5 | 2022 | 5300 | 0.390 |
Why?
|
| Anxiety | 7 | 2016 | 4297 | 0.390 |
Why?
|
| Atrial Fibrillation | 7 | 2023 | 5034 | 0.390 |
Why?
|
| Aortic Aneurysm, Thoracic | 4 | 2011 | 686 | 0.380 |
Why?
|
| Anticoagulants | 7 | 2019 | 4599 | 0.380 |
Why?
|
| Obesity | 11 | 2023 | 12745 | 0.380 |
Why?
|
| Angina Pectoris | 4 | 2021 | 977 | 0.370 |
Why?
|
| Sex Factors | 10 | 2020 | 10397 | 0.370 |
Why?
|
| Ambulatory Care | 5 | 2016 | 2708 | 0.370 |
Why?
|
| Hospitalists | 1 | 2014 | 305 | 0.370 |
Why?
|
| Angina Pectoris, Variant | 1 | 2010 | 55 | 0.370 |
Why?
|
| Platelet Aggregation Inhibitors | 6 | 2014 | 3068 | 0.360 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 1790 | 0.360 |
Why?
|
| Patient Selection | 4 | 2016 | 4215 | 0.360 |
Why?
|
| Tomography, X-Ray Computed | 13 | 2023 | 20129 | 0.360 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2021 | 550 | 0.360 |
Why?
|
| Antidepressive Agents | 7 | 2013 | 2838 | 0.360 |
Why?
|
| Comorbidity | 19 | 2024 | 10388 | 0.350 |
Why?
|
| Heart Valve Prosthesis | 1 | 2018 | 1488 | 0.350 |
Why?
|
| Early Diagnosis | 1 | 2015 | 1184 | 0.350 |
Why?
|
| Myocardial Contraction | 2 | 2014 | 1585 | 0.350 |
Why?
|
| Evidence-Based Medicine | 6 | 2018 | 3610 | 0.350 |
Why?
|
| Isoenzymes | 7 | 2007 | 1726 | 0.340 |
Why?
|
| Erythropoietin | 3 | 2009 | 726 | 0.340 |
Why?
|
| Depressive Disorder, Major | 9 | 2010 | 4644 | 0.340 |
Why?
|
| Adenosine | 1 | 2014 | 825 | 0.340 |
Why?
|
| Arrhythmias, Cardiac | 7 | 2014 | 2268 | 0.340 |
Why?
|
| Cardiomyopathies | 4 | 2022 | 1912 | 0.340 |
Why?
|
| Body Mass Index | 8 | 2021 | 12720 | 0.330 |
Why?
|
| Osteoprotegerin | 1 | 2009 | 176 | 0.330 |
Why?
|
| Cooperative Behavior | 4 | 2016 | 1504 | 0.330 |
Why?
|
| Length of Stay | 6 | 2021 | 6309 | 0.330 |
Why?
|
| Hemorrhage | 4 | 2013 | 3461 | 0.330 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2016 | 6538 | 0.330 |
Why?
|
| Receptors, Interleukin | 1 | 2010 | 245 | 0.330 |
Why?
|
| Adult | 65 | 2022 | 214055 | 0.320 |
Why?
|
| Odds Ratio | 15 | 2018 | 9849 | 0.320 |
Why?
|
| Ticlopidine | 1 | 2014 | 899 | 0.320 |
Why?
|
| Endpoint Determination | 6 | 2020 | 601 | 0.320 |
Why?
|
| Age Factors | 15 | 2021 | 18370 | 0.320 |
Why?
|
| American Heart Association | 4 | 2023 | 1056 | 0.320 |
Why?
|
| Necrosis | 7 | 2017 | 1643 | 0.320 |
Why?
|
| Reproducibility of Results | 16 | 2018 | 19905 | 0.320 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2013 | 1676 | 0.320 |
Why?
|
| Postoperative Complications | 9 | 2019 | 15295 | 0.320 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3133 | 0.320 |
Why?
|
| Hypertrophy, Left Ventricular | 4 | 2024 | 859 | 0.320 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3240 | 0.310 |
Why?
|
| Endothelium, Vascular | 3 | 2018 | 4456 | 0.310 |
Why?
|
| Blood Glucose | 3 | 2017 | 6256 | 0.310 |
Why?
|
| Hyponatremia | 2 | 2010 | 298 | 0.310 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2023 | 1536 | 0.310 |
Why?
|
| Anemia | 4 | 2009 | 1506 | 0.300 |
Why?
|
| Massachusetts | 10 | 2019 | 8663 | 0.300 |
Why?
|
| Area Under Curve | 6 | 2015 | 1654 | 0.300 |
Why?
|
| Hospital Mortality | 12 | 2021 | 5317 | 0.290 |
Why?
|
| Coronary Care Units | 3 | 2018 | 214 | 0.290 |
Why?
|
| Retrospective Studies | 31 | 2022 | 77449 | 0.290 |
Why?
|
| Myxoma | 1 | 2007 | 130 | 0.290 |
Why?
|
| Radiography, Thoracic | 3 | 2010 | 1265 | 0.280 |
Why?
|
| Economics, Hospital | 2 | 2019 | 213 | 0.280 |
Why?
|
| Linear Models | 8 | 2016 | 5952 | 0.280 |
Why?
|
| Attitude to Health | 1 | 2015 | 2052 | 0.280 |
Why?
|
| Marfan Syndrome | 3 | 2007 | 240 | 0.280 |
Why?
|
| Aortic Valve Stenosis | 1 | 2018 | 1965 | 0.270 |
Why?
|
| Pandemics | 3 | 2020 | 8388 | 0.270 |
Why?
|
| North America | 3 | 2019 | 1249 | 0.270 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2007 | 316 | 0.270 |
Why?
|
| Radiation Dosage | 3 | 2018 | 1928 | 0.270 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 4 | 2022 | 3047 | 0.260 |
Why?
|
| Syndrome | 9 | 2014 | 3251 | 0.260 |
Why?
|
| Drug Hypersensitivity | 1 | 2014 | 884 | 0.260 |
Why?
|
| Motor Activity | 1 | 2015 | 2714 | 0.260 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 5535 | 0.260 |
Why?
|
| Echocardiography, Doppler | 4 | 2019 | 935 | 0.260 |
Why?
|
| Brain Ischemia | 2 | 2009 | 3265 | 0.250 |
Why?
|
| Health Status | 8 | 2024 | 4034 | 0.250 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2011 | 3537 | 0.250 |
Why?
|
| Hemoglobins | 2 | 2009 | 1534 | 0.250 |
Why?
|
| Analysis of Variance | 4 | 2019 | 6365 | 0.250 |
Why?
|
| Reference Values | 9 | 2019 | 4982 | 0.240 |
Why?
|
| Physicians | 3 | 2014 | 4567 | 0.240 |
Why?
|
| Sepsis | 3 | 2008 | 2593 | 0.240 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2006 | 426 | 0.240 |
Why?
|
| Postoperative Care | 1 | 2011 | 1486 | 0.240 |
Why?
|
| Long QT Syndrome | 3 | 2014 | 453 | 0.240 |
Why?
|
| Embolism | 1 | 2007 | 408 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2017 | 9959 | 0.240 |
Why?
|
| Heart Neoplasms | 1 | 2007 | 374 | 0.240 |
Why?
|
| Biomedical Research | 2 | 2017 | 3309 | 0.230 |
Why?
|
| Oxygen | 2 | 2017 | 4189 | 0.230 |
Why?
|
| Depressive Disorder | 3 | 2013 | 3748 | 0.230 |
Why?
|
| Patient Discharge | 7 | 2020 | 3313 | 0.230 |
Why?
|
| Up-Regulation | 4 | 2018 | 4217 | 0.230 |
Why?
|
| Guideline Adherence | 4 | 2023 | 2266 | 0.230 |
Why?
|
| Confidence Intervals | 6 | 2019 | 2971 | 0.220 |
Why?
|
| Sex Characteristics | 2 | 2020 | 2585 | 0.220 |
Why?
|
| Research Design | 3 | 2017 | 5987 | 0.220 |
Why?
|
| Aldehyde Reductase | 1 | 2022 | 65 | 0.220 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2022 | 10943 | 0.220 |
Why?
|
| Angiopoietin-2 | 1 | 2023 | 173 | 0.220 |
Why?
|
| Angioplasty, Balloon, Coronary | 5 | 2018 | 1873 | 0.210 |
Why?
|
| Cross-Sectional Studies | 14 | 2019 | 25043 | 0.210 |
Why?
|
| Drug Therapy | 1 | 2005 | 497 | 0.210 |
Why?
|
| Patient Care | 2 | 2018 | 640 | 0.210 |
Why?
|
| Aortic Rupture | 1 | 2005 | 310 | 0.210 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 719 | 0.210 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2022 | 149 | 0.210 |
Why?
|
| Lipid Metabolism | 1 | 2011 | 1889 | 0.210 |
Why?
|
| Nerve Tissue Proteins | 2 | 2005 | 4462 | 0.210 |
Why?
|
| Diabetic Angiopathies | 1 | 2007 | 818 | 0.210 |
Why?
|
| Atherosclerosis | 4 | 2023 | 3445 | 0.210 |
Why?
|
| Psychiatric Status Rating Scales | 6 | 2013 | 6038 | 0.210 |
Why?
|
| Thrombocytopenia | 2 | 2000 | 1179 | 0.200 |
Why?
|
| Recovery of Function | 4 | 2020 | 2925 | 0.200 |
Why?
|
| Myocytes, Cardiac | 3 | 2021 | 1637 | 0.200 |
Why?
|
| Emergency Medical Services | 5 | 2017 | 1917 | 0.200 |
Why?
|
| Cholesterol, LDL | 3 | 2021 | 2356 | 0.200 |
Why?
|
| Censuses | 1 | 2022 | 200 | 0.200 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2023 | 424 | 0.200 |
Why?
|
| Tachycardia, Ventricular | 1 | 2010 | 1273 | 0.190 |
Why?
|
| Point-of-Care Systems | 5 | 2011 | 1177 | 0.190 |
Why?
|
| Substance-Related Disorders | 2 | 2017 | 4258 | 0.190 |
Why?
|
| Chi-Square Distribution | 5 | 2015 | 3508 | 0.190 |
Why?
|
| Critical Illness | 4 | 2017 | 2670 | 0.190 |
Why?
|
| Relaxin | 1 | 2020 | 37 | 0.190 |
Why?
|
| Interleukin-18 | 1 | 2022 | 249 | 0.190 |
Why?
|
| Apolipoprotein A-I | 2 | 2011 | 281 | 0.190 |
Why?
|
| Osteopontin | 1 | 2022 | 296 | 0.190 |
Why?
|
| Adiponectin | 2 | 2020 | 1100 | 0.180 |
Why?
|
| Wind | 1 | 2020 | 38 | 0.180 |
Why?
|
| Ischemic Attack, Transient | 2 | 2016 | 935 | 0.180 |
Why?
|
| Erythrocytes | 1 | 2009 | 2455 | 0.180 |
Why?
|
| Databases, Factual | 3 | 2021 | 7729 | 0.180 |
Why?
|
| Risk | 7 | 2016 | 9687 | 0.180 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 13695 | 0.180 |
Why?
|
| Standard of Care | 2 | 2016 | 564 | 0.180 |
Why?
|
| Evolution, Molecular | 1 | 2009 | 1940 | 0.180 |
Why?
|
| Boston | 8 | 2019 | 9313 | 0.180 |
Why?
|
| Hospitals, University | 2 | 2019 | 571 | 0.180 |
Why?
|
| Decision Trees | 2 | 2017 | 506 | 0.180 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 1107 | 0.180 |
Why?
|
| Double-Blind Method | 5 | 2022 | 12026 | 0.180 |
Why?
|
| Graft Rejection | 1 | 2013 | 4397 | 0.180 |
Why?
|
| Regression Analysis | 6 | 2016 | 6459 | 0.170 |
Why?
|
| Heart Transplantation | 1 | 2013 | 3110 | 0.170 |
Why?
|
| Pharmacological Phenomena | 1 | 2019 | 11 | 0.170 |
Why?
|
| Bayes Theorem | 2 | 2023 | 2309 | 0.170 |
Why?
|
| Choice Behavior | 1 | 2005 | 803 | 0.170 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2023 | 349 | 0.170 |
Why?
|
| Patient Admission | 2 | 2019 | 1380 | 0.170 |
Why?
|
| Myocardial Revascularization | 2 | 2018 | 841 | 0.170 |
Why?
|
| Blood Chemical Analysis | 3 | 2015 | 440 | 0.170 |
Why?
|
| Blood Pressure | 6 | 2021 | 8554 | 0.170 |
Why?
|
| Blood Urea Nitrogen | 3 | 2011 | 191 | 0.170 |
Why?
|
| Thrombosis | 4 | 2019 | 2968 | 0.170 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2010 | 1066 | 0.170 |
Why?
|
| Nutrition Surveys | 2 | 2023 | 1660 | 0.170 |
Why?
|
| Creatine Kinase, MB Form | 6 | 2006 | 214 | 0.170 |
Why?
|
| Hypothermia, Induced | 2 | 2017 | 752 | 0.170 |
Why?
|
| Coronary Sinus | 2 | 2016 | 87 | 0.160 |
Why?
|
| Menopause, Premature | 1 | 2019 | 132 | 0.160 |
Why?
|
| Meta-Analysis as Topic | 2 | 2013 | 1344 | 0.160 |
Why?
|
| Emergency Medicine | 1 | 2008 | 1207 | 0.160 |
Why?
|
| Running | 3 | 2008 | 480 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 2282 | 0.160 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2024 | 489 | 0.160 |
Why?
|
| Statistics as Topic | 4 | 2020 | 2373 | 0.160 |
Why?
|
| Critical Care | 3 | 2013 | 2647 | 0.160 |
Why?
|
| Kidney Failure, Chronic | 2 | 2010 | 2538 | 0.160 |
Why?
|
| Death, Sudden, Cardiac | 4 | 2010 | 1541 | 0.150 |
Why?
|
| Anti-Anxiety Agents | 2 | 2013 | 390 | 0.150 |
Why?
|
| Exercise Tolerance | 1 | 2022 | 770 | 0.150 |
Why?
|
| Probability | 6 | 2021 | 2505 | 0.150 |
Why?
|
| Immunoassay | 3 | 2017 | 752 | 0.150 |
Why?
|
| Myocardial Perfusion Imaging | 2 | 2013 | 554 | 0.150 |
Why?
|
| Principal Component Analysis | 1 | 2020 | 940 | 0.150 |
Why?
|
| Heart Injuries | 1 | 2019 | 210 | 0.150 |
Why?
|
| Organizational Innovation | 1 | 2020 | 559 | 0.150 |
Why?
|
| Health Services Misuse | 1 | 2019 | 243 | 0.150 |
Why?
|
| Risk Reduction Behavior | 2 | 2020 | 1125 | 0.150 |
Why?
|
| Logistic Models | 12 | 2014 | 13408 | 0.150 |
Why?
|
| United States Food and Drug Administration | 3 | 2020 | 1584 | 0.140 |
Why?
|
| Homeostasis | 1 | 2008 | 3340 | 0.140 |
Why?
|
| Thrombin | 1 | 1999 | 598 | 0.140 |
Why?
|
| Forecasting | 3 | 2013 | 2951 | 0.140 |
Why?
|
| Drug Labeling | 1 | 2018 | 233 | 0.140 |
Why?
|
| Single-Blind Method | 4 | 2017 | 1590 | 0.140 |
Why?
|
| Triage | 2 | 2016 | 976 | 0.140 |
Why?
|
| Angiotensins | 1 | 2017 | 151 | 0.140 |
Why?
|
| Statistics, Nonparametric | 4 | 2010 | 2886 | 0.140 |
Why?
|
| Hypotension | 3 | 2020 | 884 | 0.140 |
Why?
|
| Calcitonin Gene-Related Peptide | 2 | 2015 | 306 | 0.140 |
Why?
|
| Metabolomics | 2 | 2023 | 1484 | 0.140 |
Why?
|
| Hospitals, Teaching | 1 | 2021 | 1179 | 0.140 |
Why?
|
| Evaluation Studies as Topic | 1 | 2018 | 1681 | 0.140 |
Why?
|
| Terminology as Topic | 2 | 2020 | 1547 | 0.130 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2022 | 851 | 0.130 |
Why?
|
| Drug Monitoring | 2 | 2019 | 956 | 0.130 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2020 | 293 | 0.130 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 3 | 2020 | 153 | 0.130 |
Why?
|
| Inflammation Mediators | 2 | 2017 | 1889 | 0.130 |
Why?
|
| Ventilator Weaning | 1 | 2016 | 148 | 0.130 |
Why?
|
| Cerebrovascular Trauma | 1 | 2015 | 23 | 0.130 |
Why?
|
| Methamphetamine | 1 | 2017 | 154 | 0.130 |
Why?
|
| Emotions | 3 | 2017 | 2661 | 0.130 |
Why?
|
| Myoglobin | 3 | 2005 | 160 | 0.130 |
Why?
|
| Albumins | 2 | 2011 | 569 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2023 | 2015 | 0.130 |
Why?
|
| Autonomic Nervous System | 1 | 2020 | 671 | 0.130 |
Why?
|
| Animals | 13 | 2022 | 168757 | 0.130 |
Why?
|
| Mass Screening | 3 | 2010 | 5255 | 0.130 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2017 | 365 | 0.130 |
Why?
|
| Acetylglucosaminidase | 1 | 2014 | 70 | 0.130 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2016 | 1422 | 0.130 |
Why?
|
| Extracellular Matrix | 2 | 2014 | 1741 | 0.130 |
Why?
|
| Medicare | 3 | 2024 | 6566 | 0.130 |
Why?
|
| Torsades de Pointes | 2 | 2013 | 78 | 0.130 |
Why?
|
| Societies, Medical | 3 | 2019 | 3743 | 0.130 |
Why?
|
| Lipoproteins, HDL | 1 | 2019 | 638 | 0.120 |
Why?
|
| Patient Care Team | 3 | 2016 | 2531 | 0.120 |
Why?
|
| CA-125 Antigen | 1 | 2017 | 286 | 0.120 |
Why?
|
| Clinical Competence | 2 | 2008 | 4687 | 0.120 |
Why?
|
| Troponin C | 2 | 2011 | 25 | 0.120 |
Why?
|
| Health Status Indicators | 1 | 2020 | 969 | 0.120 |
Why?
|
| Thrombolytic Therapy | 2 | 2018 | 2161 | 0.120 |
Why?
|
| Pre-Eclampsia | 1 | 2024 | 1200 | 0.120 |
Why?
|
| Stress, Psychological | 3 | 2014 | 4245 | 0.120 |
Why?
|
| Risk Adjustment | 1 | 2018 | 594 | 0.120 |
Why?
|
| Hospital Costs | 1 | 2021 | 985 | 0.120 |
Why?
|
| Mortality | 4 | 2019 | 2864 | 0.120 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2016 | 315 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2020 | 1147 | 0.120 |
Why?
|
| Oxidative Stress | 2 | 2018 | 3086 | 0.120 |
Why?
|
| Forearm | 1 | 2016 | 409 | 0.120 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 2019 | 373 | 0.120 |
Why?
|
| Defibrillators, Implantable | 2 | 2020 | 1440 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 3870 | 0.120 |
Why?
|
| Postoperative Period | 3 | 2010 | 1842 | 0.120 |
Why?
|
| Heart Arrest | 2 | 2017 | 1470 | 0.120 |
Why?
|
| Primary Health Care | 2 | 2011 | 4558 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2008 | 3843 | 0.120 |
Why?
|
| Aspirin | 2 | 2010 | 3282 | 0.120 |
Why?
|
| Reimbursement, Incentive | 1 | 2019 | 540 | 0.120 |
Why?
|
| Protein C | 2 | 2007 | 138 | 0.120 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 500 | 0.120 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 2376 | 0.110 |
Why?
|
| Feasibility Studies | 5 | 2017 | 5078 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2016 | 2684 | 0.110 |
Why?
|
| Vietnam | 1 | 2014 | 408 | 0.110 |
Why?
|
| Limit of Detection | 1 | 2014 | 265 | 0.110 |
Why?
|
| Congresses as Topic | 1 | 2018 | 764 | 0.110 |
Why?
|
| Aortic Valve | 2 | 2018 | 1922 | 0.110 |
Why?
|
| Apolipoproteins C | 1 | 1992 | 59 | 0.110 |
Why?
|
| Infection Control | 1 | 2020 | 966 | 0.110 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2023 | 789 | 0.110 |
Why?
|
| Drug Discovery | 1 | 2021 | 1058 | 0.110 |
Why?
|
| Cholesterol | 1 | 2022 | 2917 | 0.110 |
Why?
|
| Blood Specimen Collection | 1 | 2014 | 246 | 0.110 |
Why?
|
| Cyanides | 1 | 2013 | 83 | 0.110 |
Why?
|
| Health Behavior | 2 | 2017 | 2636 | 0.110 |
Why?
|
| Riboflavin | 1 | 2013 | 108 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 3508 | 0.110 |
Why?
|
| Case-Control Studies | 9 | 2019 | 21746 | 0.110 |
Why?
|
| Anthracyclines | 2 | 2012 | 288 | 0.110 |
Why?
|
| Pneumonia, Bacterial | 1 | 2015 | 316 | 0.100 |
Why?
|
| Antidotes | 1 | 2013 | 138 | 0.100 |
Why?
|
| Electroconvulsive Therapy | 3 | 2011 | 477 | 0.100 |
Why?
|
| Diastole | 2 | 2012 | 791 | 0.100 |
Why?
|
| Vasodilator Agents | 1 | 2016 | 977 | 0.100 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2014 | 434 | 0.100 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2008 | 581 | 0.100 |
Why?
|
| Phenotype | 2 | 2023 | 16365 | 0.100 |
Why?
|
| Oxidation-Reduction | 2 | 2023 | 2187 | 0.100 |
Why?
|
| Diagnostic Errors | 1 | 2019 | 1257 | 0.100 |
Why?
|
| Digoxin | 1 | 2012 | 250 | 0.100 |
Why?
|
| Ultrasonography | 4 | 2012 | 5985 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 2203 | 0.100 |
Why?
|
| Diffusion of Innovation | 1 | 2017 | 725 | 0.100 |
Why?
|
| Losartan | 1 | 2013 | 299 | 0.100 |
Why?
|
| Sodium-Glucose Transporter 2 | 2 | 2023 | 85 | 0.100 |
Why?
|
| Physical Examination | 3 | 2008 | 1237 | 0.100 |
Why?
|
| Social Work, Psychiatric | 1 | 2011 | 24 | 0.100 |
Why?
|
| Algorithms | 6 | 2024 | 13881 | 0.100 |
Why?
|
| Arginine Vasopressin | 1 | 2011 | 130 | 0.100 |
Why?
|
| Critical Pathways | 2 | 2018 | 476 | 0.100 |
Why?
|
| Saphenous Vein | 1 | 2014 | 532 | 0.100 |
Why?
|
| Fibrinogen | 1 | 2014 | 894 | 0.100 |
Why?
|
| Pain Measurement | 1 | 2001 | 3420 | 0.100 |
Why?
|
| Osmolar Concentration | 2 | 2009 | 683 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 4 | 2016 | 5391 | 0.100 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2014 | 549 | 0.100 |
Why?
|
| Coronary Circulation | 1 | 2017 | 1572 | 0.100 |
Why?
|
| Smoking | 3 | 2021 | 8987 | 0.100 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2013 | 1107 | 0.090 |
Why?
|
| Child of Impaired Parents | 1 | 2014 | 455 | 0.090 |
Why?
|
| Austria | 1 | 2011 | 203 | 0.090 |
Why?
|
| Patient Care Planning | 1 | 2016 | 921 | 0.090 |
Why?
|
| Galectins | 1 | 2013 | 268 | 0.090 |
Why?
|
| Cardiac Tamponade | 2 | 2009 | 173 | 0.090 |
Why?
|
| Fibrosis | 3 | 2022 | 2029 | 0.090 |
Why?
|
| Heart-Assist Devices | 1 | 2020 | 1194 | 0.090 |
Why?
|
| Magnesium | 2 | 2010 | 813 | 0.090 |
Why?
|
| Europe | 4 | 2020 | 3339 | 0.090 |
Why?
|
| Catheter Ablation | 1 | 2023 | 2758 | 0.090 |
Why?
|
| Haloperidol | 1 | 2011 | 397 | 0.090 |
Why?
|
| Personality Inventory | 2 | 2010 | 1030 | 0.090 |
Why?
|
| Longitudinal Studies | 5 | 2023 | 13989 | 0.090 |
Why?
|
| Rest | 1 | 2014 | 901 | 0.090 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2011 | 402 | 0.090 |
Why?
|
| Spain | 1 | 2011 | 465 | 0.090 |
Why?
|
| Laboratories, Hospital | 1 | 2011 | 194 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 1157 | 0.090 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2011 | 300 | 0.090 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2009 | 63 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2022 | 3255 | 0.090 |
Why?
|
| Glycoproteins | 1 | 2017 | 2263 | 0.090 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2009 | 114 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2017 | 1002 | 0.080 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 1637 | 0.080 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2007 | 1133 | 0.080 |
Why?
|
| Atrial Function, Left | 1 | 2010 | 173 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2020 | 1797 | 0.080 |
Why?
|
| Heparitin Sulfate | 2 | 2000 | 225 | 0.080 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 472 | 0.080 |
Why?
|
| Antipsychotic Agents | 2 | 2013 | 3057 | 0.080 |
Why?
|
| Insulin | 1 | 2023 | 6580 | 0.080 |
Why?
|
| Epidemiologic Methods | 3 | 2008 | 1364 | 0.080 |
Why?
|
| Insurance, Health | 1 | 2021 | 2494 | 0.080 |
Why?
|
| Solubility | 3 | 2016 | 1085 | 0.080 |
Why?
|
| Norway | 1 | 2009 | 448 | 0.080 |
Why?
|
| Medical Records | 3 | 2006 | 1413 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 1831 | 0.080 |
Why?
|
| Recurrence | 5 | 2008 | 8340 | 0.080 |
Why?
|
| Sex Distribution | 4 | 2009 | 2297 | 0.080 |
Why?
|
| Occupational Exposure | 1 | 2018 | 1796 | 0.080 |
Why?
|
| Surgical Procedures, Operative | 1 | 2019 | 1876 | 0.080 |
Why?
|
| Bronchial Arteries | 1 | 2007 | 20 | 0.080 |
Why?
|
| Neurotransmitter Agents | 1 | 2011 | 647 | 0.080 |
Why?
|
| Emergencies | 2 | 2006 | 1170 | 0.080 |
Why?
|
| Cell Size | 1 | 2009 | 643 | 0.080 |
Why?
|
| New York | 1 | 2010 | 886 | 0.080 |
Why?
|
| Lipoproteins, LDL | 1 | 2011 | 640 | 0.080 |
Why?
|
| Benchmarking | 3 | 2018 | 1042 | 0.080 |
Why?
|
| Heart Rate | 2 | 2011 | 4091 | 0.080 |
Why?
|
| Stents | 3 | 2014 | 3280 | 0.080 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2013 | 783 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2013 | 11524 | 0.070 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2007 | 101 | 0.070 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 2418 | 0.070 |
Why?
|
| Hemodynamics | 2 | 2014 | 4199 | 0.070 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 2007 | 97 | 0.070 |
Why?
|
| Asthma | 1 | 2006 | 6011 | 0.070 |
Why?
|
| Health Care Costs | 2 | 2021 | 3209 | 0.070 |
Why?
|
| Embolectomy | 1 | 2007 | 120 | 0.070 |
Why?
|
| Denmark | 1 | 2009 | 738 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 1622 | 0.070 |
Why?
|
| Interleukin-6 | 1 | 2016 | 3200 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2013 | 8324 | 0.070 |
Why?
|
| Psychotherapy | 2 | 2013 | 1643 | 0.070 |
Why?
|
| Myocardial Stunning | 1 | 2006 | 68 | 0.070 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2008 | 125 | 0.070 |
Why?
|
| Age Distribution | 3 | 2015 | 2902 | 0.070 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 281 | 0.070 |
Why?
|
| Delirium | 1 | 2018 | 1609 | 0.070 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2008 | 500 | 0.070 |
Why?
|
| Fibrinolysis | 1 | 2007 | 322 | 0.070 |
Why?
|
| Paresis | 1 | 2007 | 179 | 0.070 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2007 | 224 | 0.070 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2019 | 964 | 0.070 |
Why?
|
| Behavior Therapy | 1 | 2012 | 865 | 0.070 |
Why?
|
| General Surgery | 1 | 2017 | 1636 | 0.070 |
Why?
|
| Heart Murmurs | 1 | 2006 | 94 | 0.070 |
Why?
|
| Hematinics | 1 | 2009 | 281 | 0.070 |
Why?
|
| Diagnostic Imaging | 2 | 2018 | 3507 | 0.070 |
Why?
|
| Coronary Occlusion | 1 | 2009 | 304 | 0.070 |
Why?
|
| Radiographic Image Enhancement | 1 | 2011 | 885 | 0.070 |
Why?
|
| Pain | 1 | 2001 | 4986 | 0.070 |
Why?
|
| Young Adult | 5 | 2022 | 56430 | 0.070 |
Why?
|
| Medicaid | 1 | 2019 | 2736 | 0.070 |
Why?
|
| Mental Health | 2 | 2017 | 3019 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2015 | 4554 | 0.070 |
Why?
|
| Suicidal Ideation | 1 | 2014 | 1248 | 0.070 |
Why?
|
| Interleukins | 1 | 2010 | 791 | 0.060 |
Why?
|
| Anesthesia, Spinal | 1 | 2008 | 269 | 0.060 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2004 | 23 | 0.060 |
Why?
|
| Weight Loss | 1 | 2016 | 2622 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2018 | 3528 | 0.060 |
Why?
|
| Radiography | 4 | 2009 | 7023 | 0.060 |
Why?
|
| Vascular Surgical Procedures | 2 | 2011 | 1475 | 0.060 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2013 | 1265 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2013 | 4776 | 0.060 |
Why?
|
| Syncope | 1 | 2007 | 429 | 0.060 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2008 | 476 | 0.060 |
Why?
|
| Blood Coagulation Disorders | 1 | 2007 | 337 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2015 | 2916 | 0.060 |
Why?
|
| Chromosome Mapping | 1 | 1992 | 4740 | 0.060 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2004 | 86 | 0.060 |
Why?
|
| Biological Assay | 1 | 2007 | 652 | 0.060 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2024 | 70 | 0.060 |
Why?
|
| Hyperglycemia | 1 | 2013 | 1373 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2012 | 13815 | 0.060 |
Why?
|
| Models, Biological | 1 | 2020 | 9583 | 0.060 |
Why?
|
| Iatrogenic Disease | 2 | 2009 | 547 | 0.060 |
Why?
|
| Apoprotein(a) | 1 | 2023 | 18 | 0.060 |
Why?
|
| Preoperative Period | 2 | 2019 | 549 | 0.060 |
Why?
|
| Acute-Phase Proteins | 2 | 2015 | 262 | 0.060 |
Why?
|
| Membrane Glycoproteins | 1 | 2014 | 3768 | 0.060 |
Why?
|
| Neointima | 2 | 2014 | 135 | 0.060 |
Why?
|
| Molecular Weight | 1 | 2006 | 2255 | 0.060 |
Why?
|
| Genetic Testing | 1 | 2016 | 3444 | 0.060 |
Why?
|
| Patient Education as Topic | 2 | 2011 | 2278 | 0.060 |
Why?
|
| Fibroblast Growth Factors | 1 | 2009 | 879 | 0.060 |
Why?
|
| Recombinant Proteins | 3 | 2020 | 6622 | 0.060 |
Why?
|
| Apolipoproteins A | 1 | 2023 | 94 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2018 | 4371 | 0.050 |
Why?
|
| Bundle-Branch Block | 2 | 2017 | 270 | 0.050 |
Why?
|
| Balloon Occlusion | 1 | 2003 | 126 | 0.050 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 18111 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2011 | 1990 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2007 | 1850 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2003 | 233 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2012 | 2046 | 0.050 |
Why?
|
| Exercise Test | 1 | 2010 | 2074 | 0.050 |
Why?
|
| Drug Therapy, Combination | 3 | 2001 | 6489 | 0.050 |
Why?
|
| Apoptosis | 1 | 2018 | 9727 | 0.050 |
Why?
|
| Physical Fitness | 1 | 2006 | 733 | 0.050 |
Why?
|
| Judgment | 1 | 2004 | 281 | 0.050 |
Why?
|
| Radial Artery | 1 | 2003 | 194 | 0.050 |
Why?
|
| Mitral Valve | 1 | 2010 | 1491 | 0.050 |
Why?
|
| Tomography, Optical Coherence | 1 | 2014 | 2657 | 0.050 |
Why?
|
| Rare Diseases | 1 | 2006 | 553 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2003 | 482 | 0.050 |
Why?
|
| Data Interpretation, Statistical | 2 | 2013 | 2716 | 0.050 |
Why?
|
| Apolipoproteins B | 1 | 2023 | 374 | 0.050 |
Why?
|
| Aorta, Thoracic | 1 | 2007 | 1082 | 0.050 |
Why?
|
| Microspheres | 1 | 2003 | 777 | 0.050 |
Why?
|
| Committee Membership | 1 | 2020 | 15 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2015 | 4043 | 0.050 |
Why?
|
| Telemedicine | 2 | 2017 | 2872 | 0.050 |
Why?
|
| New England | 1 | 2024 | 1022 | 0.050 |
Why?
|
| APACHE | 2 | 2013 | 277 | 0.050 |
Why?
|
| Echocardiography, Stress | 1 | 2021 | 131 | 0.050 |
Why?
|
| Hematoma | 1 | 2005 | 758 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 9274 | 0.050 |
Why?
|
| Polypharmacy | 1 | 2023 | 294 | 0.050 |
Why?
|
| Platelet Factor 4 | 1 | 2000 | 129 | 0.050 |
Why?
|
| Tricuspid Valve | 1 | 2023 | 403 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2006 | 1462 | 0.050 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2003 | 478 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2012 | 2063 | 0.050 |
Why?
|
| Calcinosis | 1 | 2009 | 1499 | 0.050 |
Why?
|
| Blood Donors | 1 | 2002 | 355 | 0.050 |
Why?
|
| Ancrod | 1 | 1999 | 7 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2002 | 1420 | 0.040 |
Why?
|
| Dermatan Sulfate | 1 | 1999 | 35 | 0.040 |
Why?
|
| Hirudin Therapy | 1 | 1999 | 43 | 0.040 |
Why?
|
| Taxoids | 2 | 2013 | 666 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2008 | 1365 | 0.040 |
Why?
|
| Phospholipids | 1 | 2023 | 784 | 0.040 |
Why?
|
| Gangrene | 1 | 1999 | 82 | 0.040 |
Why?
|
| Product Labeling | 1 | 2020 | 79 | 0.040 |
Why?
|
| Mental Health Services | 1 | 2011 | 1643 | 0.040 |
Why?
|
| Morbidity | 2 | 2019 | 1769 | 0.040 |
Why?
|
| Relaxation Therapy | 1 | 2000 | 178 | 0.040 |
Why?
|
| Chondroitin Sulfates | 1 | 1999 | 187 | 0.040 |
Why?
|
| Pipecolic Acids | 1 | 1999 | 76 | 0.040 |
Why?
|
| Observer Variation | 1 | 2005 | 2593 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2008 | 1786 | 0.040 |
Why?
|
| Cross Reactions | 1 | 2000 | 841 | 0.040 |
Why?
|
| Fluorocarbons | 1 | 2003 | 452 | 0.040 |
Why?
|
| Albuminuria | 1 | 2022 | 682 | 0.040 |
Why?
|
| North Carolina | 1 | 2019 | 315 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2004 | 1609 | 0.040 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 1177 | 0.040 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2008 | 1186 | 0.040 |
Why?
|
| Hirudins | 1 | 1999 | 183 | 0.040 |
Why?
|
| Plasma Volume | 1 | 2017 | 36 | 0.040 |
Why?
|
| Edema, Cardiac | 1 | 2017 | 18 | 0.040 |
Why?
|
| Safety | 1 | 2003 | 1186 | 0.040 |
Why?
|
| District of Columbia | 1 | 2018 | 157 | 0.040 |
Why?
|
| Thrombophilia | 1 | 2000 | 305 | 0.040 |
Why?
|
| Interdisciplinary Communication | 2 | 2016 | 950 | 0.040 |
Why?
|
| International Cooperation | 1 | 2004 | 1420 | 0.040 |
Why?
|
| Ceruloplasmin | 1 | 2017 | 56 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2000 | 675 | 0.040 |
Why?
|
| Electric Countershock | 1 | 2020 | 534 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 1992 | 13033 | 0.040 |
Why?
|
| Streptococcal Infections | 1 | 1981 | 638 | 0.040 |
Why?
|
| Ovariectomy | 1 | 2019 | 661 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 841 | 0.040 |
Why?
|
| Clinical Coding | 1 | 2018 | 171 | 0.040 |
Why?
|
| Myocardial Reperfusion | 1 | 2018 | 351 | 0.040 |
Why?
|
| Tissue Survival | 1 | 2017 | 118 | 0.040 |
Why?
|
| Breast Neoplasms | 3 | 2013 | 20822 | 0.040 |
Why?
|
| Forced Expiratory Volume | 1 | 2022 | 1743 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 15519 | 0.040 |
Why?
|
| Cost Savings | 2 | 2016 | 926 | 0.040 |
Why?
|
| Platelet Activation | 1 | 2000 | 673 | 0.040 |
Why?
|
| Hypolipidemic Agents | 1 | 2021 | 604 | 0.040 |
Why?
|
| Ventricular Dysfunction | 1 | 2017 | 143 | 0.040 |
Why?
|
| Athletic Injuries | 1 | 2006 | 1154 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2017 | 346 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2021 | 775 | 0.040 |
Why?
|
| Italy | 1 | 2018 | 832 | 0.030 |
Why?
|
| Haptoglobins | 1 | 2017 | 165 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 1999 | 798 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 7785 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2020 | 695 | 0.030 |
Why?
|
| Netherlands | 1 | 2020 | 2170 | 0.030 |
Why?
|
| Arginine | 1 | 1999 | 944 | 0.030 |
Why?
|
| Antithrombins | 1 | 2018 | 304 | 0.030 |
Why?
|
| Internationality | 2 | 2013 | 1003 | 0.030 |
Why?
|
| Brain | 2 | 2015 | 26385 | 0.030 |
Why?
|
| Hospitals | 2 | 2019 | 3952 | 0.030 |
Why?
|
| Pulmonary Edema | 1 | 2017 | 414 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2019 | 789 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2010 | 3712 | 0.030 |
Why?
|
| Vascular Patency | 2 | 2007 | 886 | 0.030 |
Why?
|
| Furin | 1 | 2014 | 46 | 0.030 |
Why?
|
| Vena Cava, Inferior | 1 | 2017 | 440 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2000 | 1607 | 0.030 |
Why?
|
| Bipolar Disorder | 1 | 2011 | 5027 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2019 | 745 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2017 | 930 | 0.030 |
Why?
|
| Epitopes | 1 | 2000 | 2571 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2000 | 1504 | 0.030 |
Why?
|
| Overweight | 1 | 2005 | 2371 | 0.030 |
Why?
|
| Telephone | 1 | 2017 | 617 | 0.030 |
Why?
|
| Pyridones | 1 | 2018 | 712 | 0.030 |
Why?
|
| Exercise | 1 | 2010 | 5615 | 0.030 |
Why?
|
| Aging | 1 | 2012 | 8664 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2017 | 1155 | 0.030 |
Why?
|
| Nitroprusside | 1 | 2013 | 275 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2019 | 1183 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2015 | 458 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2003 | 2921 | 0.030 |
Why?
|
| Discriminant Analysis | 1 | 2013 | 235 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2016 | 1005 | 0.030 |
Why?
|
| Physical Exertion | 2 | 2008 | 695 | 0.030 |
Why?
|
| Diet | 1 | 2010 | 7939 | 0.030 |
Why?
|
| Inosine | 1 | 2013 | 133 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2016 | 593 | 0.030 |
Why?
|
| Germany | 1 | 2014 | 862 | 0.030 |
Why?
|
| Video Games | 1 | 2014 | 184 | 0.030 |
Why?
|
| Restriction Mapping | 1 | 1992 | 878 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 551 | 0.030 |
Why?
|
| Combined Modality Therapy | 3 | 2011 | 8642 | 0.030 |
Why?
|
| Dizziness | 1 | 2014 | 251 | 0.030 |
Why?
|
| Menopause | 1 | 2019 | 1626 | 0.030 |
Why?
|
| Models, Economic | 1 | 2016 | 713 | 0.030 |
Why?
|
| Aftercare | 1 | 2017 | 866 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1992 | 1085 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2017 | 2618 | 0.020 |
Why?
|
| Apolipoprotein C-III | 1 | 1992 | 202 | 0.020 |
Why?
|
| Peptides | 1 | 2003 | 4409 | 0.020 |
Why?
|
| Glycosylation | 1 | 2014 | 1126 | 0.020 |
Why?
|
| Receptors, Virus | 1 | 2014 | 648 | 0.020 |
Why?
|
| Patient Preference | 1 | 2018 | 890 | 0.020 |
Why?
|
| Neoplasms | 1 | 2020 | 21683 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2014 | 1185 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2017 | 899 | 0.020 |
Why?
|
| Bile Acids and Salts | 1 | 2013 | 367 | 0.020 |
Why?
|
| Warfarin | 1 | 1999 | 1496 | 0.020 |
Why?
|
| Propensity Score | 1 | 2017 | 1781 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2019 | 2488 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2014 | 729 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 1801 | 0.020 |
Why?
|
| Veins | 1 | 2014 | 770 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2020 | 2635 | 0.020 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2008 | 1953 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1981 | 2541 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2017 | 3913 | 0.020 |
Why?
|
| Sulfonamides | 1 | 1999 | 1938 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2010 | 520 | 0.020 |
Why?
|
| Health Resources | 1 | 2016 | 911 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2016 | 1683 | 0.020 |
Why?
|
| Renal Plasma Flow | 1 | 2009 | 30 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 1616 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2014 | 1072 | 0.020 |
Why?
|
| Pregnancy | 3 | 2024 | 29144 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 1677 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1992 | 2327 | 0.020 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2011 | 585 | 0.020 |
Why?
|
| Species Specificity | 1 | 1992 | 2478 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1992 | 2839 | 0.020 |
Why?
|
| Quinolones | 1 | 2011 | 367 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2012 | 1588 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2018 | 1972 | 0.020 |
Why?
|
| Liver Failure, Acute | 1 | 2009 | 165 | 0.020 |
Why?
|
| Weight Gain | 1 | 2017 | 2292 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 1375 | 0.020 |
Why?
|
| Carotid Stenosis | 1 | 2014 | 854 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2013 | 2234 | 0.020 |
Why?
|
| Renal Artery | 1 | 2009 | 398 | 0.020 |
Why?
|
| Acidosis, Lactic | 1 | 2008 | 142 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2013 | 1442 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2010 | 1173 | 0.020 |
Why?
|
| Heart Block | 1 | 2008 | 410 | 0.020 |
Why?
|
| Rabbits | 1 | 2013 | 4894 | 0.020 |
Why?
|
| Decision Making | 1 | 2019 | 3887 | 0.020 |
Why?
|
| Phosphates | 1 | 2009 | 786 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2007 | 569 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 35421 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 4933 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2008 | 23403 | 0.020 |
Why?
|
| Reference Standards | 1 | 2009 | 1025 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 1992 | 2126 | 0.020 |
Why?
|
| Resuscitation | 1 | 2010 | 658 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9239 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 12261 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2004 | 6600 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2008 | 783 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2020 | 10481 | 0.020 |
Why?
|
| Adolescent | 2 | 2003 | 85781 | 0.020 |
Why?
|
| Life Tables | 1 | 2004 | 370 | 0.010 |
Why?
|
| Suicide | 1 | 2014 | 1477 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 1981 | 6364 | 0.010 |
Why?
|
| Respiratory Tract Diseases | 1 | 2009 | 722 | 0.010 |
Why?
|
| Sample Size | 1 | 2007 | 845 | 0.010 |
Why?
|
| National Health Programs | 1 | 2007 | 445 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 2006 | 338 | 0.010 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2006 | 638 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2011 | 5179 | 0.010 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2009 | 794 | 0.010 |
Why?
|
| Lactic Acid | 1 | 2008 | 1133 | 0.010 |
Why?
|
| Sodium | 1 | 2008 | 1623 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 2576 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2006 | 836 | 0.010 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2003 | 364 | 0.010 |
Why?
|
| Case Management | 1 | 2004 | 286 | 0.010 |
Why?
|
| Data Collection | 1 | 2011 | 3341 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2009 | 1130 | 0.010 |
Why?
|
| Alcohol-Related Disorders | 1 | 2004 | 234 | 0.010 |
Why?
|
| Gene Expression | 1 | 2015 | 7799 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2010 | 1912 | 0.010 |
Why?
|
| Canada | 1 | 2007 | 2065 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2004 | 981 | 0.010 |
Why?
|
| Zebrafish | 1 | 2013 | 2994 | 0.010 |
Why?
|
| Coitus | 1 | 2002 | 133 | 0.010 |
Why?
|
| Rupture, Spontaneous | 1 | 2002 | 354 | 0.010 |
Why?
|
| Base Sequence | 1 | 1992 | 12797 | 0.010 |
Why?
|
| Piperazines | 1 | 2011 | 2488 | 0.010 |
Why?
|
| Fatigue | 1 | 2008 | 1531 | 0.010 |
Why?
|
| Psychometrics | 1 | 2010 | 3002 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2000 | 305 | 0.010 |
Why?
|
| Hospitals, General | 1 | 2004 | 749 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2009 | 1855 | 0.010 |
Why?
|
| Consciousness Disorders | 1 | 2004 | 418 | 0.010 |
Why?
|
| Anesthesia | 1 | 2010 | 1561 | 0.010 |
Why?
|
| Lung | 1 | 2017 | 9856 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 2000 | 537 | 0.010 |
Why?
|
| Coronary Thrombosis | 1 | 2002 | 495 | 0.010 |
Why?
|
| DNA | 1 | 1992 | 7301 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1992 | 7722 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2009 | 6895 | 0.010 |
Why?
|
| Glycosaminoglycans | 1 | 2000 | 624 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2000 | 835 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2006 | 1392 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2006 | 1956 | 0.010 |
Why?
|
| Vitamin D | 1 | 2009 | 3223 | 0.010 |
Why?
|
| Calcium | 1 | 2008 | 5756 | 0.010 |
Why?
|
| Health Expenditures | 1 | 2007 | 2348 | 0.010 |
Why?
|
| Cattle | 1 | 2000 | 3922 | 0.010 |
Why?
|
| Cell Division | 1 | 2000 | 4568 | 0.010 |
Why?
|
| Aorta | 1 | 2000 | 2061 | 0.010 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2004 | 4266 | 0.000 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2003 | 8949 | 0.000 |
Why?
|
| Mice | 1 | 1992 | 81183 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 2000 | 19229 | 0.000 |
Why?
|